CRA was retained by plaintiffs ViiV Healthcare and other companies in their high-profile US patent litigation against Gilead Sciences, Inc., regarding HIV medications.
CRA delivered a cross-practice collaboration led by testifying expert Ray Sims, Vice President in CRA’s Intellectual Property Practice. Mr. Sims was supported by members of the firm’s Life Sciences Practice, including Vice President Andrew Tepperman and Associate Principal Taylor Rubinato. Following the exchange of multiple expert reports and depositions, the parties reached a settlement shortly before trial.
The settlement terms provided for a $1.25 billion upfront payment by Gilead, along with an ongoing royalty on future sales of Biktarvy, the blockbuster drug at issue.